PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Benzbromarone→

Benzbromarone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
3562-84-3
Molecular formula
C17H12Br2O3
Molecular weight
424.1 g/mol
Drug class
Uricosuric agentnon-purine xanthine oxidase inhibitor
Mechanism of action
Lowers serum urate through uricosuric activity by reducing renal tubular urate reabsorption; published pharmacology also describes non-purine xanthine oxidase inhibition. The relative contribution of each action depends on the source and product.
Indications / reported uses
  • Treatment of chronic hyperuricaemia and gout in selected patients where authorised, generally when first-line urate-lowering therapy is unsuitable or ineffective. It is not for treatment of an acute gout attack. Use is limited in many jurisdictions because of serious hepatotoxicity, including reports of fatal liver injury.

Sources: NIDDK LiverTox — Benzbromarone · Bahrain Ministry of Health drug information — Benzbromarone · PubChem summary (LiverTox/ChEBI records) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Benzbromarone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Benzbromarone Permitted Daily Exposure (PDE) report (the Benzbromarone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Benzbromarone Occupational Exposure Limit (OEL) report (the Benzbromarone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.